HOW did GLP-1RAs bring about a paradigm shift in the guidelines of managing T2DM: A path to gluco-cardio Centricity.
GLP-1RAs 如何在管理T2DM的指引中帶來範式轉變:通往葡萄糖心臟中心的道路。
Indian Heart J 2023-03-08
The Impact of Glucagon-Like Peptide-1 Receptor Agonist on the Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis and Systematic Review.
糖尿病患者中胰高血糖素樣肽-1受體激動劑對心血管結果的影響:一項荟萃分析和系統性回顧。
Cardiol Res 2023-08-11
Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiovascular Risk Management in Patients With Type 2 Diabetes Mellitus: A Systematic Review.
GLP-1受體激動劑在第2型糖尿病患者心血管風險管理中的作用:系統性回顧。
Cureus 2023-10-21
Cardiovascular protection significantly depends on HbA1c improvement with GLP-1RAs but not with SGLT2 is in type 2 diabetes: A narrative review.
GLP-1RAs對心血管保護的重要性顯著取決於HbA1c的改善,而SGLT2在2型糖尿病中則不然:一篇敘述性綜述。
Diabetes Metab 2024-03-19
Association Between the Magnitude of Glycemic Control and Body Weight Loss With GLP-1 Receptor Agonists and Risk of Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-analyses of Randomized Diabetes Cardiovascular Outcomes Trials.
GLP-1 受體激動劑對血糖控制程度和體重減輕幅度與動脈粥樣硬化心血管疾病風險之關聯:糖尿病心血管結果試驗的系統性回顧和荟萃分析。
Cardiovasc Drugs Ther 2024-01-12
A Review and Meta-Analysis of the Safety and Efficacy of Using Glucagon-like Peptide-1 Receptor Agonists.
使用胰高血糖素樣肽-1受體激動劑的安全性和有效性評論與荟萃分析。
Medicina (Kaunas) 2024-03-30
Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials.
糖尿病患者和非糖尿病患者中胰高血糖素樣肽-1受體激動劑的心血管和腎臟結果:隨機安慰劑對照試驗的荟萃分析。
Am J Prev Cardiol 2024-05-23
Glucagon-Like Peptide-1 Receptor Agonists and Major Adverse Cardiovascular Events in Patients With and Without Diabetes: A Meta-Analysis of Randomized-Controlled Trials.
糖尿病患者和非糖尿病患者中胰高血糖素樣肽-1受體激動劑與主要不良心血管事件:隨機對照試驗的荟萃分析。
Clin Cardiol 2024-07-02
Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic and Weight Loss Drugs.
GLP-1 受體激動劑的心血管保護特性:不僅僅是糖尿病和減重藥物。
J Clin Med 2024-08-29